339 related articles for article (PubMed ID: 29486358)
1. Antifungal susceptibility testing results of New Zealand yeast isolates, 2001-2015: Impact of recent CLSI breakpoints and epidemiological cut-off values for Candida and other yeast species.
Morris AJ; Rogers K; McKinney WP; Roberts SA; Freeman JT
J Glob Antimicrob Resist; 2018 Sep; 14():72-77. PubMed ID: 29486358
[TBL] [Abstract][Full Text] [Related]
2. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
Karabıçak N; Alem N
Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
[TBL] [Abstract][Full Text] [Related]
3. Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in
Espinel-Ingroff A; Turnidge J; Alastruey-Izquierdo A; Botterel F; Canton E; Castro C; Chen YC; Chen Y; Chryssanthou E; Dannaoui E; Garcia-Effron G; Gonzalez GM; Govender NP; Guinea J; Kidd S; Lackner M; Lass-Flörl C; Linares-Sicilia MJ; López-Soria L; Magobo R; Pelaez T; Quindós G; Rodriguez-Iglesia MA; Ruiz MA; Sánchez-Reus F; Sanguinetti M; Shields R; Szweda P; Tortorano A; Wengenack NL; Bramati S; Cavanna C; DeLuca C; Gelmi M; Grancini A; Lombardi G; Meletiadis J; Negri CE; Passera M; Peman J; Prigitano A; Sala E; Tejada M
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323038
[TBL] [Abstract][Full Text] [Related]
4. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
5. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
[TBL] [Abstract][Full Text] [Related]
6. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.
Posteraro B; Spanu T; Fiori B; De Maio F; De Carolis E; Giaquinto A; Prete V; De Angelis G; Torelli R; D'Inzeo T; Vella A; De Luca A; Tumbarello M; Ricciardi W; Sanguinetti M
Antimicrob Agents Chemother; 2015 Jul; 59(7):3944-55. PubMed ID: 25896705
[TBL] [Abstract][Full Text] [Related]
7. Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent
Espinel-Ingroff A; Sasso M; Turnidge J; Arendrup M; Botterel F; Bourgeois N; Bouteille B; Canton E; Cassaing S; Dannaoui E; Dehais M; Delhaes L; Dupont D; Fekkar A; Fuller J; Garcia-Effron G; Garcia J; Gonzalez GM; Govender NP; Guegan H; Guinea J; Houzé S; Lass-Flörl C; Pelaez T; Forastiero A; Lackner M; Magobo R
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0109321. PubMed ID: 34370582
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
[TBL] [Abstract][Full Text] [Related]
9. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskou A; Ramani R
Diagn Microbiol Infect Dis; 2012 Aug; 73(4):365-8. PubMed ID: 22726528
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and Antifungal Susceptibility of
Badiee P; Boekhout T; Haddadi P; Mohammadi R; Ghadimi-Moghadam A; Soltani J; Zarei Mahmoudabadi A; Ayatollahi Mousavi SA; Najafzadeh MJ; Diba K; Salimi-Khorashad AR; Amin Shahidi M; Ghasemi F; Jafarian H
Microbiol Spectr; 2022 Dec; 10(6):e0245322. PubMed ID: 36445122
[TBL] [Abstract][Full Text] [Related]
12. Multicentre study to determine the Etest epidemiological cut-off values of antifungal drugs in Candida spp. and Aspergillus fumigatus species complex.
Salsé M; Gangneux JP; Cassaing S; Delhaes L; Fekkar A; Dupont D; Botterel F; Costa D; Bourgeois N; Bouteille B; Houzé S; Dannaoui E; Guegan H; Charpentier E; Persat F; Favennec L; Lachaud L; Sasso M
Clin Microbiol Infect; 2019 Dec; 25(12):1546-1552. PubMed ID: 31082487
[TBL] [Abstract][Full Text] [Related]
13. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds.
Espinel-Ingroff A; Turnidge J
Rev Iberoam Micol; 2016; 33(2):63-75. PubMed ID: 27296911
[TBL] [Abstract][Full Text] [Related]
14. Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method.
Cantón E; Pemán J; Iñiguez C; Hervás D; Lopez-Hontangas JL; Pina-Vaz C; Camarena JJ; Campos-Herrero I; García-García I; García-Tapia AM; Guna R; Merino P; Pérez del Molino L; Rubio C; Suárez A;
J Clin Microbiol; 2013 Aug; 51(8):2691-5. PubMed ID: 23761155
[TBL] [Abstract][Full Text] [Related]
15. Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints.
Chen YC; Kuo SF; Chen FJ; Lee CH
Mycoses; 2017 Feb; 60(2):89-95. PubMed ID: 27621210
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Two Commercial Broth Microdilution Methods Using Different Interpretive Criteria for the Detection of Molecular Mechanisms of Acquired Azole and Echinocandin Resistance in Four Common
Lim HJ; Shin JH; Kim MN; Yong D; Byun SA; Choi MJ; Lee SY; Won EJ; Kee SJ; Kim SH; Shin MG
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32900684
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Six Antifungal Susceptibilities of 11
Lee H; Choi SH; Oh J; Koo J; Lee HJ; Cho SI; Shin JH; Lee HK; Kim SY; Lee CH; Kim YR; Sohn YH; Kim WJ; Ryu SW; Sung GH; Kim J
Microbiol Spectr; 2022 Apr; 10(2):e0125321. PubMed ID: 35384691
[TBL] [Abstract][Full Text] [Related]
18. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671
[TBL] [Abstract][Full Text] [Related]
19. Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom.
Borman AM; Muller J; Walsh-Quantick J; Szekely A; Patterson Z; Palmer MD; Fraser M; Johnson EM
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182537
[TBL] [Abstract][Full Text] [Related]
20. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
